Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.38 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.38 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6709482 | 1.00 | ALDH1A1 (0.45) | ALDH1A1KDM4ESMN1; SMN2RAB9ALMNA | |
| SCHEMBL6709488 | 0.83 | ALDH1A1 (0.46) | ALDH1A1KDM4ESMN1; SMN2RAB9ALMNA | |
| SCHEMBL6711020 | 0.83 | LMNA (0.48) | ALDH1A1KDM4ESMN1; SMN2RAB9ALMNA | |
| SCHEMBL6711016 | 0.83 | LMNA (0.48) | ALDH1A1KDM4ESMN1; SMN2RAB9ALMNA | |
| SCHEMBL6709484 | 0.83 | ALDH1A1 (0.46) | ALDH1A1KDM4ESMN1; SMN2RAB9ALMNA | |
| SCHEMBL6710843 | 0.82 | SMN1; SMN2 (0.46) | KDM4ESMN1; SMN2RAB9ALMNATSHR | |
| SCHEMBL6709470 | 0.82 | SMN1; SMN2 (0.46) | KDM4ESMN1; SMN2RAB9ALMNATSHR | |
| SCHEMBL6971245 | 0.82 | ALDH1A1 (0.45) | ALDH1A1KDM4ESMN1; SMN2RAB9ALMNA | |
| SCHEMBL6711230 | 0.82 | LMNA (0.53) | ALDH1A1KDM4ESMN1; SMN2RAB9ALMNA | |
| SCHEMBL6711226 | 0.82 | LMNA (0.53) | ALDH1A1KDM4ESMN1; SMN2RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040024209-A1 | 1-Aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents | SCHNUTE MARK E (US) | 2004-02-05 | — | — | US | disclosed |
| US-6653307-B2 | Such as N-(4-chlorobenzyl)-6-(4-morpholinylmethyl)-4-oxo-1-phenyl-1,4-dihydro-3-quinolinecarboxamide for treatment of herpes virus; viral DNA polymerase inhibitors | PHARMACIA & UPJOHN COMPANY | 2003-11-25 | — | — | US | disclosed |
| EP-1292575-A2 | 1-ARYL-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20020103220-A1 | 1-Aryl-4oxo-1,4-Dihydro-3-quinolinecarboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-08-01 | — | — | US | disclosed |
| WO-2001098275-A2 | 1-ARYL-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
| EP-1140850-A1 | QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6248739-B1 | DNA POLYMERASE INHIBITORS EFFECTIVE AGAINST HERPESVIRUSES | PHARMACIA & UPJOHN COMPANY | 2001-06-19 | — | — | US | disclosed |
| WO-2000040561-A1 | QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024209-A1 | 1-Aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, IRF3 | ALDH1A1 668/4885KDM4E 314/4885SMN1; SMN2 4052/4885 |
| US-20020103220-A1 | 1-Aryl-4oxo-1,4-Dihydro-3-quinolinecarboxamides as antiviral agents | ZC3HAV1, IRF3, ZC3HAV1L | ALDH1A1 463/4885KDM4E 178/4885SMN1; SMN2 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.